Tekton Research
Welcome,         Profile    Billing    Logout  
 0 Trials 
20 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Adetona, Olutola
NCT04909021: Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months

Recruiting
1c
63
US
Investigational RSV vaccine MV-012-968 (Dosage 1), Investigational RSV vaccine MV-012-968 (Dosage 2), Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose), Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose), Placebo (single-dose), Placebo (two-dose)
Meissa Vaccines, Inc.
Respiratory Syncytial Virus (RSV)
10/23
10/23
ALIA-1758-101, NCT06406348: A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants

Recruiting
1
52
US
ALIA-1758, Placebo
Aliada Therapeutics
Alzheimer Disease
01/25
01/25
Etokhana, Kenneth
NCT05973006: Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines

Completed
3
400
US
NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, NVX-CoV2601, Prototype/XBB.1.5 Bivalent Vaccine (5 µg), Omicron XBB.1.5 (sub-variant)SARS-CoV-2 rS /Matrix-M Adjuvant
Novavax
COVID-19
04/24
09/24
NCT03621670 / 2016-003268-37: Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

Completed
3
1196
Europe, US
Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix, Hiberix, Rotarix, M-M-R II, Varivax, Placebo (saline water), Prevnar 20
GlaxoSmithKline
Infections, Meningococcal
12/24
12/24
NCT06693895: A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age

Not yet recruiting
3
750
Europe, US, RoW
Investigational varicella vaccine, Marketed varicella vaccine, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
GlaxoSmithKline
Chickenpox
07/26
12/26
NCT05468736: Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

Active, not recruiting
2/3
3600
Europe, US, RoW
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), NVX-CoV2373, Placebo, Sodium chloride 0.9% (BP, sterile)
Novavax
COVID-19
01/24
10/25
NCT05084508 / 2022-001910-21: A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

Completed
2
800
Europe, US, RoW
Investigational varicella vaccine low potency, Investigational varicella vaccine medium potency, Investigational varicella vaccine high potency, Marketed varicella vaccine Lot 1, Marketed varicella vaccine Lot 2, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, 13-valent pneumococcal conjugate vaccine
GlaxoSmithKline, GlaxoSmithKline Biologicals SA (GSK)
Chickenpox
02/24
06/24
NCT05412030: A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

Active, not recruiting
2
472
US
AFX3772, Prevnar 13, PCV13, Prevnar 20, PCV20
GlaxoSmithKline, Affinivax, Inc.
Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
07/26
07/26
NCT04144699: Clinical Validation of Omron WheezeScan

Recruiting
N/A
240
US
Omron Healthcare Co., Ltd., University of Wisconsin, Madison, Children's Hospital Medical Center, Cincinnati, University of Chicago
Asthma in Children, Bronchitis, Bronchiolitis
11/21
12/21
Fajardo, Xavier
NCT05412030: A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

Active, not recruiting
2
472
US
AFX3772, Prevnar 13, PCV13, Prevnar 20, PCV20
GlaxoSmithKline, Affinivax, Inc.
Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
07/26
07/26
McDonald, Jara
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
NCT05975060: A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.

Completed
2/3
660
US
XBB.1.5 Vaccine (Booster), Omicron sub variant XBB.1.5 vaccine( booster) SARS-CoV-2 rS /Matrix-M Adjuvant, XBB.1.5 Vaccine (single dose), Omicron sub variant XBB.1.5 vaccine(single dose) SARS-CoV-2 rS /Matrix-M Adjuvant
Novavax
COVID-19
11/23
05/24
NCT06143956: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Recruiting
2
1040
US, RoW
LY3305677, LY3841136, Tirzepatide, Placebo, LY3549492
Eli Lilly and Company
Obesity, Overweight
06/26
09/26
NCT06230523: A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Recruiting
2
250
US, RoW
LY3841136, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
06/25
09/25
NCT06560151: BARDA BP-I-23-001 H5 Influenza

Active, not recruiting
2
1380
US
3.75 µg H5N8 antigen plus full dose AS03A, 7.5 µg H5N8 antigen plus full dose AS03A, 15 µg H5N8 antigen plus full dose AS03A, 3.75 µg H5N8 antigen plus half dose AS03A, 7.5 µg H5N8 antigen plus half dose AS03A, 15 µg H5N8 antigen plus half dose AS03A, 3.75 µg H5N8 antigen plus MF59, 7.5 µg H5N8 antigen plus MF59, 15 µg H5N8 antigen plus MF59, 3.75 µg H5N1 antigen plus full dose AS03A, 7.5 µg H5N1 antigen plus full dose AS03A, 15 µg H5N1 antigen plus full dose AS03A
Biomedical Advanced Research and Development Authority, Rho Federal Systems Division, Inc., ICON plc
Influenza
05/25
12/25
NCT06603571: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Recruiting
2
350
US, RoW
LY3841136, Tirzepatide, Placebo
Eli Lilly and Company
Obesity, Overweight
06/26
08/26
NCT06683508: A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

Recruiting
2
275
US, RoW
LY3549492, Placebo
Eli Lilly and Company
Obesity, Overweight
04/26
09/26
NCT06124807: A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

Active, not recruiting
2
179
US, RoW
LY3305677, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
01/25
05/25
NCT05975840: Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults

Completed
1/2
518
US
FLU Q-PAN H5N8 Formulation 1, AS03B, AS03A, FLU Q-PAN H5N8 Formulation 2
GlaxoSmithKline
Influenza, Human
12/23
05/24
Diaz, Gerardo
NCT05975060: A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.

Completed
2/3
660
US
XBB.1.5 Vaccine (Booster), Omicron sub variant XBB.1.5 vaccine( booster) SARS-CoV-2 rS /Matrix-M Adjuvant, XBB.1.5 Vaccine (single dose), Omicron sub variant XBB.1.5 vaccine(single dose) SARS-CoV-2 rS /Matrix-M Adjuvant
Novavax
COVID-19
11/23
05/24

Download Options